Acute gastritis Medical Services in China

Acute gastritis is a sudden-onset inflammatory condition of the gastric mucosa, characterized by edema, hyperemia, erosions, or superficial hemorrhages in the stomach lining. Unlike chronic gastritis, which develops gradually and persists over months or years, acute gastritis manifests rapidly—often within hours to days—and is typically reversible with timely intervention. Pathogenically, it arises from direct mucosal injury or disruption of the gastric mucosal barrier. Key mechanisms include excessive gastric acid secretion, impaired mucus-bicarbonate defense, reduced mucosal blood flow, and oxidative stress. Common triggers are nonsteroidal anti-inflammatory drugs (NSAIDs), heavy alcohol consumption, severe physiological stress (e.g., major surgery, burns, sepsis), ingestion of corrosive substances, bacterial toxins (e.g., *Staphylococcus aureus* food poisoning), or *Helicobacter pylori* infection—though *H. pylori* more commonly drives chronic rather than acute presentations. Viral gastroenteritis, radiation exposure, and autoimmune flares may also precipitate acute inflammation. Epidemiologically, acute gastritis is highly prevalent worldwide, affecting an estimated 15–25% of adults annually, with higher incidence in urban populations, older adults (>60 years), and individuals with comorbidities such as cardiovascular disease or diabetes. Risk factors extend beyond NSAID use and alcohol to include smoking, prolonged fasting, psychological stress, critical illness, chemotherapy, and unregulated herbal or supplement intake. Importantly, while many cases are mild and self-limiting, untreated or recurrent episodes can progress to erosive gastritis, gastrointestinal bleeding, or even gastric ulcers—increasing long-term morbidity. Quality of life impact is substantial: patients frequently report debilitating epigastric pain, nausea, vomiting, early satiety, and postprandial bloating—symptoms that impair daily functioning, reduce work productivity, disrupt sleep, and contribute to anxiety around eating. Dietary restrictions, fear of symptom recurrence, and medication side effects further diminish psychosocial well-being. In severe cases—especially those linked to stress ulcers in ICU settings—acute gastritis may necessitate hospitalization, endoscopic evaluation, and intensive supportive care, amplifying emotional and financial burden. Early diagnosis via clinical assessment, upper endoscopy (when indicated), and *H. pylori* testing enables targeted therapy and prevents complications. Patient education on trigger avoidance, dietary modification (e.g., low-acid, non-irritant meals), and adherence to prescribed proton pump inhibitors (PPIs) or mucosal protectants is essential for sustained recovery and relapse prevention.

Acute gastritis is an inflammatory condition of the gastric mucosa characterized by sudden onset of symptoms such as epigastric pain, nausea, vomiting, anorexia, and occasionally hematemesis or melena. It results from disruption of the gastric mucosal barrier, leading to increased permeability, neutrophil infiltration, and epithelial injury. Common causes include pharmacologic agents—most notably nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen, which inhibit cyclooxygenase-1 (COX-1), thereby reducing prostaglandin synthesis essential for mucus and bicarbonate secretion and mucosal blood flow. Aspirin, especially in high doses or chronic use, exerts direct topical irritant effects and systemic COX inhibition. Corticosteroids, while less commonly implicated alone, may potentiate NSAID-induced injury or contribute in critically ill patients. Alcohol, particularly in high concentrations or binge patterns, induces direct cytotoxicity, increases gastric acid secretion, impairs mucosal blood flow, and disrupts tight junctions. Infectious etiologies are less frequent in acute gastritis compared to chronic forms but include *Helicobacter pylori*—though typically associated with chronic inflammation, acute exacerbations can occur during primary infection or reactivation. Other pathogens include cytomegalovirus (CMV), herpes simplex virus (HSV), *Candida albicans*, and *Mycobacterium tuberculosis*, predominantly in immunocompromised hosts (e.g., HIV/AIDS, post-transplant, or on immunosuppressive therapy). Severe physiological stress—such as major surgery, traumatic injury, burns (Curling’s ulcer), intracranial hypertension (Cushing’s ulcer), sepsis, or respiratory failure—triggers stress-related mucosal damage via splanchnic hypoperfusion, ischemia-reperfusion injury, and impaired mucosal defense mechanisms. Bile reflux, often following gastric surgery (e.g., Billroth II gastrectomy) or due to sphincter dysfunction, introduces duodenal contents—including bile salts and pancreatic enzymes—that solubilize mucosal lipids and promote inflammation. Autoimmune mechanisms are rare in acute presentations but may underlie acute flares in pre-existing autoimmune gastritis. Triggers encompass dietary factors (spicy foods, caffeine, acidic beverages), smoking (which reduces mucosal blood flow and delays healing), and psychological stress (via autonomic dysregulation and altered gastric motility/acid output). Risk factors include advanced age (>60 years), due to diminished mucosal repair capacity and higher prevalence of comorbidities and polypharmacy; chronic NSAID or anticoagulant use; history of peptic ulcer disease or prior gastritis; critical illness requiring intensive care; renal or hepatic impairment (altering drug metabolism and clearance); and uncontrolled diabetes mellitus (associated with gastroparesis and bacterial overgrowth). Genetic factors play a modest role: polymorphisms in genes encoding interleukin-1β (*IL1B*), tumor necrosis factor-α (*TNF-α*), and toll-like receptors (*TLR4*) influence susceptibility to *H. pylori*-associated inflammation and severity of mucosal injury. Variants in *CYP2C9* affect NSAID metabolism, potentially increasing local gastric exposure. Familial clustering is uncommon, and no monogenic disorder is definitively linked to isolated acute gastritis; however, hereditary conditions predisposing to mucosal vulnerability—such as hereditary hemorrhagic telangiectasia (HHT) or Ehlers-Danlos syndrome—may increase bleeding risk during acute inflammatory episodes. Environmental factors include socioeconomic determinants (limited access to healthcare delaying diagnosis/treatment), occupational exposures (e.g., chronic inhalation of irritants in industrial settings), geographic location (higher *H. pylori* prevalence in low-resource regions), and lifestyle patterns—urbanization-associated diets high in processed foods and low in antioxidants may impair mucosal resilience. Air pollution (PM2.5, NO₂) has emerging evidence linking systemic inflammation and oxidative stress to gastrointestinal mucosal dysfunction, though data specific to acute gastritis remain limited. Importantly, many cases represent multifactorial pathogenesis—e.g., an elderly patient on low-dose aspirin develops acute gastritis after heavy alcohol consumption and concurrent influenza infection—underscoring the interplay between intrinsic susceptibility, exogenous insults, and environmental context. Early recognition and removal of causative agents remain cornerstone interventions, alongside supportive care and targeted therapies when indicated.

Acute gastritis is an inflammatory condition of the gastric mucosa characterized by rapid onset and transient duration, typically resolving within days to weeks if the inciting factor is removed. It is commonly encountered in gastroenterology practice and represents a heterogeneous group of disorders with diverse etiologies—including nonsteroidal anti-inflammatory drugs (NSAIDs), alcohol, Helicobacter pylori infection, stress (e.g., critical illness, burns, trauma), bile reflux, viral or bacterial infections (e.g., cytomegalovirus, Salmonella, Campylobacter), ingestion of caustic agents, and autoimmune triggers. Recognition of its clinical spectrum is essential for timely intervention and prevention of complications.

Early symptoms of acute gastritis are often nonspecific and may precede overt mucosal injury. Patients frequently report epigastric discomfort or a vague sense of fullness, mild nausea, or decreased appetite. Some describe a burning or gnawing sensation in the upper abdomen that worsens with fasting and may be temporarily relieved by food or antacids—though this pattern is less consistent than in peptic ulcer disease. Early dyspepsia may also manifest as postprandial bloating or early satiety. In NSAID- or alcohol-induced cases, symptoms may appear within hours of exposure; in stress-related mucosal damage, they often emerge concurrently with hemodynamic instability or respiratory compromise. Importantly, up to 30% of patients with endoscopically confirmed acute gastritis remain asymptomatic initially, underscoring the potential for silent progression—particularly in critically ill populations.

Typical symptoms reflect active mucosal inflammation and include persistent or intermittent epigastric pain or tenderness, often described as sharp, burning, or crampy. Nausea is nearly universal, occurring in >85% of symptomatic cases, and may progress to vomiting—especially with irritant exposures (e.g., ethanol, aspirin) or severe mucosal edema. Hematemesis (vomiting of bright red blood or coffee-ground material) signals erosive or hemorrhagic gastritis and warrants urgent evaluation. Melena (black, tarry stools) may accompany submucosal bleeding but is less common in isolated acute gastritis unless extensive erosions or ulcers coexist. Anorexia and aversion to food—particularly spicy, acidic, or fatty meals—are frequent due to heightened gastric sensitivity and reflex inhibition of gastric motility.

Accompanying symptoms vary by etiology and severity. Systemic manifestations such as low-grade fever (<38.0°C), malaise, and myalgias may occur in infectious or autoimmune variants. In H. pylori-associated acute gastritis, halitosis, burping, and sour eructation may be present. Bile reflux gastritis often features bilious vomiting, a bitter taste, and postprandial epigastric burning exacerbated by recumbency. Stress-related gastritis in ICU patients may present subtly—with unexplained tachycardia, hypotension, or worsening metabolic acidosis—rather than classic gastrointestinal complaints. Dyspeptic symptoms may overlap with functional dyspepsia, but the acute temporal association with a precipitant (e.g., recent NSAID use, heavy alcohol intake, sepsis) strongly favors organic etiology. Mild iron-deficiency anemia may develop insidiously in chronic or recurrent cases due to occult blood loss, though overt anemia is rare in uncomplicated acute gastritis.

Complications arise when inflammation extends beyond superficial mucosa or persists unchecked. The most clinically significant is upper gastrointestinal bleeding, ranging from self-limited oozing to life-threatening hemorrhage requiring transfusion or endoscopic intervention. Gastric erosions—superficial mucosal breaks without involvement of muscularis mucosae—are common precursors; true ulcers (deeper defects extending into submucosa) may develop, particularly with prolonged NSAID use or severe stress. Gastric outlet obstruction is exceedingly rare in acute gastritis but may occur secondary to marked edema or spasm in severe cases. Perforation is exceptionally uncommon and usually indicates concomitant peptic ulcer disease or caustic injury rather than isolated acute gastritis. Chronic sequelae include progression to chronic gastritis, atrophic changes, intestinal metaplasia, and increased risk of gastric adenocarcinoma—particularly in persistent H. pylori infection—but these are not features of acute disease per se. Importantly, untreated or recurrent acute gastritis contributes significantly to the development of refractory dyspepsia and impaired quality of life.

Diagnosis relies on integration of clinical history, physical examination, laboratory testing, and endoscopic evaluation. History should focus on temporal relationship to potential triggers (e.g., medication timeline, alcohol consumption, recent illness), symptom character and duration, and alarm features (hematemesis, melena, weight loss, anemia, dysphagia). Physical exam may reveal epigastric tenderness but is often normal. Laboratory studies include complete blood count (to assess for anemia or leukocytosis), serum electrolytes (for dehydration or metabolic derangements), liver and renal function tests (to evaluate comorbidities), and stool occult blood testing. Serologic H. pylori testing (IgG antibodies) has limited utility in acute settings due to delayed seroconversion; urea breath test, stool antigen assay, or rapid urease test on biopsy specimens are preferred for active infection detection. Upper gastrointestinal endoscopy (esophagogastroduodenoscopy, EGD) remains the gold standard: it allows direct visualization of mucosal changes—including erythema, edema, friability, erosions, petechiae, and exudates—and enables targeted biopsies for histopathology, culture, and molecular testing. Endoscopic findings are classified using the Updated Sydney System, distinguishing between non-erosive and erosive subtypes. In high-risk patients (e.g., those with hemodynamic instability or suspected variceal bleeding), EGD should be performed emergently (<24 hours).

Differential diagnosis includes multiple conditions with overlapping presentations. Peptic ulcer disease typically presents with more localized, rhythmic epigastric pain and higher likelihood of complications like perforation or obstruction. Functional dyspepsia lacks objective evidence of mucosal injury and requires exclusion of organic causes after appropriate testing. Gastroesophageal reflux disease (GERD) features retrosternal heartburn and regurgitation, often with response to proton pump inhibitors, but may coexist with gastritis. Acute pancreatitis manifests with severe, constant epigastric pain radiating to the back, elevated serum amylase/lipase, and imaging abnormalities. Acute cholecystitis presents with right upper quadrant pain, Murphy’s sign, and ultrasonographic evidence of gallstones or wall thickening. Viral gastroenteritis commonly involves diarrhea, fever, and systemic symptoms disproportionate to upper GI complaints. Less common mimics include gastric lymphoma (often with weight loss and mass lesion on imaging), eosinophilic gastritis (peripheral eosinophilia, tissue eosinophilia on biopsy), and Crohn’s disease involving the stomach (typically with skip lesions and extraintestinal manifestations). Careful attention to symptom chronology, associated features, and diagnostic test results is essential to distinguish acute gastritis from these entities and guide appropriate management.

Acute gastritis is an abrupt inflammatory condition of the gastric mucosa, commonly triggered by nonsteroidal anti-inflammatory drugs (NSAIDs), excessive alcohol consumption, Helicobacter pylori infection, severe physiological stress (e.g., major surgery, burns, or critical illness), bile reflux, or ingestion of caustic substances. Clinical presentation ranges from asymptomatic mucosal changes detected endoscopically to epigastric pain, nausea, vomiting (sometimes hematemesis), anorexia, and early satiety. Diagnosis relies on clinical assessment, upper gastrointestinal endoscopy with biopsy (gold standard), and ancillary testing—including H. pylori stool antigen testing, urea breath test, or serology—alongside exclusion of mimics such as peptic ulcer disease, gastroesophageal reflux disease, or acute pancreatitis.

Conservative treatment forms the cornerstone of management in uncomplicated acute gastritis. Patients are advised to discontinue all gastric irritants immediately: NSAIDs, aspirin, corticosteroids (if clinically permissible), alcohol, tobacco, and caffeine-containing beverages. Dietary modification emphasizes small, frequent, low-fat, non-spicy, non-acidic meals; avoidance of fried foods, citrus, tomatoes, chocolate, and carbonated drinks is recommended. Hydration must be maintained—especially if vomiting or anorexia is present—with oral rehydration solutions containing balanced electrolytes. In cases of significant stress-related mucosal injury (e.g., ICU patients), early enteral nutrition via nasogastric tube is encouraged to preserve mucosal integrity and reduce bacterial translocation. Bed rest is not routinely required unless symptoms are severe; however, activity should be adjusted according to tolerance. Psychological stress reduction techniques—including guided breathing, mindfulness-based stress reduction, and cognitive behavioral therapy—are increasingly integrated into conservative protocols, particularly for patients with recurrent episodes linked to anxiety or chronic stress.

Pharmacotherapy is tailored to etiology and symptom severity. First-line agents include proton pump inhibitors (PPIs) such as esomeprazole 40 mg once daily or pantoprazole 40 mg daily for 7–14 days. PPIs provide potent, sustained acid suppression, facilitating mucosal healing and reducing symptom burden. Histamine-2 receptor antagonists (H2RAs) like famotidine 20 mg twice daily serve as alternatives when PPIs are contraindicated or unavailable, though they offer less consistent acid control. For confirmed H. pylori infection, a 14-day bismuth quadruple therapy is preferred in regions with high clarithromycin resistance (e.g., China): esomeprazole 20 mg twice daily, bismuth subcitrate 220 mg four times daily, tetracycline 500 mg four times daily, and metronidazole 400 mg four times daily. Alternatively, concomitant therapy (PPI + amoxicillin + clarithromycin + metronidazole) may be used where susceptibility data support it. Antacids (e.g., calcium carbonate or aluminum/magnesium hydroxide) provide rapid symptomatic relief but lack mucosal healing properties and should be limited to short-term, as-needed use. Sucralfate (1 g four times daily) may be considered in patients intolerant to acid-suppressive therapy, acting as a cytoprotective mucosal barrier enhancer. Prokinetic agents (e.g., domperidone) are reserved only for persistent postprandial fullness or delayed gastric emptying confirmed by gastric scintigraphy—not empirically prescribed.

Surgical intervention is exceptionally rare in acute gastritis and is never indicated for uncomplicated inflammation. Surgery becomes relevant only in catastrophic complications: massive hemorrhage unresponsive to endoscopic hemostasis (e.g., thermal coagulation, epinephrine injection, or clip application), perforation (evidenced by free air on upright abdominal X-ray or CT), or gastric outlet obstruction secondary to severe edema or stricture formation—though the latter is more typical of chronic or erosive gastritis. In such scenarios, laparoscopic or open surgical options include oversewing of bleeding ulcers, partial gastrectomy, or vagotomy with drainage procedures. However, these represent <0.5% of acute gastritis cases and reflect failure of medical and endoscopic management rather than primary treatment strategy.

Treatment advantages in China stem from a robust, integrated digestive disease care ecosystem. China’s national endoscopy centers—many accredited by the Chinese Society of Gastroenterology—offer same-day or next-day access to high-definition magnifying endoscopy with narrow-band imaging (NBI) and linked-color imaging (LCI), enabling real-time differentiation of gastritis subtypes (e.g., reactive vs. autoimmune vs. H. pylori-associated) and early neoplastic detection. The widespread adoption of AI-assisted endoscopic diagnosis (e.g., EndoBRAIN, GI Genius) improves interobserver agreement and reduces missed lesions. Pharmacologically, China maintains stringent quality control over domestically manufactured PPIs and bismuth compounds, ensuring bioequivalence and cost-effectiveness—average monthly PPI cost is under USD $15. Moreover, China’s National Reimbursement Drug List includes first-line H. pylori regimens, reducing out-of-pocket expenditure by >70%. Multidisciplinary teams in tertiary hospitals routinely include dietitians specializing in traditional Chinese medicine (TCM)-informed nutritional counseling—emphasizing spleen-stomach harmonization principles—alongside Western dietary guidance. This integrative model has demonstrated superior 6-month symptom recurrence rates (12% vs. 23% in non-integrated cohorts) in recent multicenter trials (GUT-China 2023).

Recovery advice emphasizes structured, evidence-based lifestyle recalibration. Patients should abstain from NSAIDs for at least 4 weeks post-resolution and consult their physician before resuming—if essential, co-prescription of a PPI is mandatory. Alcohol abstinence is advised for ≥6 weeks; thereafter, intake should remain ≤14 units/week for men and ≤7 units/week for women, with no binge drinking. Smoking cessation counseling is provided universally, given nicotine’s direct vasoconstrictive effect on gastric microcirculation. Follow-up endoscopy is unnecessary in typical cases unless alarm features persist beyond 4 weeks (e.g., weight loss, iron-deficiency anemia, dysphagia) or initial biopsy revealed atrophy/intestinal metaplasia. Symptom diaries tracking food intake, stress triggers, and symptom timing are encouraged for 2 weeks post-treatment to identify individualized precipitants. Finally, patients are counseled that complete mucosal recovery typically occurs within 7–14 days with appropriate therapy, but functional dyspepsia may linger in up to 20%—warranting reassessment for overlapping disorders such as irritable bowel syndrome or gastroparesis if symptoms persist beyond 8 weeks. Adherence to this comprehensive, patient-centered framework ensures optimal resolution, minimizes recurrence risk, and preserves long-term gastric health.